Cartagenia and OGT Collaborate in Automated Genome Assay Data Transfer

Aiding confident clinical diagnosis

Leuven – June 11, 2010 — Cartagenia today announced that Bench, its database platform and software solution for constitutional cytogenetics, now seamlessly integrates with Oxford Gene Technology’s (OGT) CytoSure™ Interpret Software, enabling automated exchange of array comparative genomic hybridisation (aCGH) results. This integration further accelerates the work flow of clinical geneticists in routine genetic diagnosis and advances the accurate determination of a patient’s diagnosis. Further details of this new functionality will be presented in two workshops at the European Society of Human Genetics in Gothenburg from 12 - 15 June. On 12th June, OGT will present “From disease to cytogenetics research – An integrated CNV analysis platform from Oxford Gene Technology” at 12.00 in room H1. Following on from this, at 14.00 in room R4, Cartagenia will present “Routine clinical interpretation of copy number variation”.

The Cartagenia Bench database and CytoSure Interpret Software together provide a complimentary offer to technicians, medical geneticists and genetic counsellors involved in routine genetic diagnostic practice. An automated data transfer from CytoSure Interpret Software to the Bench platform ensures a smooth workflow supporting all aspects of the interpretation of Copy Number Variations (CNVs) in a clinical context. With Bench, CNV results obtained from OGT assays can easily be managed within a comprehensive database, enabling data to be shared within, and across, various facilities quickly and securely. Furthermore, users can effortlessly carry out patient comparisons, as well as generate suggested candidate genes that are likely to be responsible for an altered patient phenotype. This, in combination with advanced capture and annotation of patient clinical details and specifically designed custom reporting for clinicians, results in accurate patient diagnosis and equips the lab with end-to-end workflow support in routine diagnostics.

Cartagenia will be exhibiting at ESHG 2010 on booth B-632.

OGT will be exhibiting at ESHG 2010 on booth B-550.

About Cartagenia

Cartagenia provides patient-based diagnostic knowledge, systems, and services which equip genetics laboratories to perform clinically relevant genetic analyses and obtain results quickly, efficiently, and in a way that enables clinicians to deliver high-standing genetic diagnosis and counseling services.

Bench is Cartagenia’s intelligent database platform and software solution for constitutional cytogenetics enabling rapid clinical interpretation of copy number alterations in patient samples. Cartagenia Bench features support for genotype-phenotype correlation analysis, automatic generation of clinical reports, customizable data entry and data exchange possibilities, semi-automated workflows, management, storage, and organization of assay data, and much more. For a demonstration or trial, please contact info@cartagenia.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other purpose.